Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system: Preparation, characterization, and in vivo evaluation

Journal of Biomaterials Applications

Volumn 27, Issue 4, 2012, Pages 391-402

  Chen, Xingwei ^a   Li, Xinru ^a   Zhou, Yanxia ^a   Wang, Xiaoning ^a   Zhang, Yanhui ^a   Fan, Yating ^a   Huang, Yanqing ^a   Liu, Yan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

allergic conjunctivitis; Chitosan; cornea penetration; glucose phosphate; ocular irritation; thermosensitive hydrogel

Indexed keywords

ALLERGIC CONJUNCTIVITIS; CORNEA PENETRATION; D-GLUCOSE; EYE DROPS; GELATION TEMPERATURE; GELATION TIME; IN-SITU; IN-VIVO; MODEL DRUGS; OCULAR DRUG DELIVERY SYSTEMS; OCULAR IRRITATION; PHYSIOLOGICAL TEMPERATURE; RAPID RELEASE; RESIDENCE TIME; ROOM TEMPERATURE; SOL-GEL TRANSITIONS; SUSTAINED RELEASE; THERMO-SENSITIVE HYDROGEL; TRANSITION BEHAVIOR;

CHITOSAN; DRUG DELIVERY; GELATION; GLUCOSE; ORGANIC SOLVENTS; SOL-GEL PROCESS; SOL-GELS; SOLUTIONS;

HYDROGELS;

CETIRIZINE; CHITOSAN; GLUCOSE 1 PHOSPHATE; GLUCOSE PHOSPHATE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOCETIRIZINE;

ALLERGIC CONJUNCTIVITIS; ANIMAL; ARTICLE; CHEMISTRY; CORNEA; DELAYED RELEASE FORMULATION; DRUG EFFECT; FEMALE; GUINEA PIG; HYDROGEL; MALE; METABOLISM; PHASE TRANSITION; RABBIT; TEMPERATURE;

ANIMALS; CETIRIZINE; CHITOSAN; CONJUNCTIVITIS, ALLERGIC; CORNEA; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOSEPHOSPHATES; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HYDROGEL; MALE; PHASE TRANSITION; RABBITS; TEMPERATURE;

EID: 84858801060     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328211406563     Document Type: Article

References (57)

1. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability ii: evaluation of pilocarpine. J Pharm Sci. 1977 ; 66: 1222-1228
2. Makoid MC, Sieg JW, Robinson JR. Corneal drug absorption: an illustration of parallel first-order absorption and rapid loss of drug from absorption depot. J Pharm Sci. 1976 ; 65: 150-153
3. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci. 1998 ; 6: 105-112
4. Simamora P, Nadkarni SR, Lee YC, Yalkowsky SH. Controlled delivery of pilocarpine. 2. in-vivo evaluation of gelfoam (r) device. Int J Pharm. 1998 ; 170: 209-214
5. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res. 1998 ; 17: 33-58
6. Ding S. Recent developments in ophthalmic drug delivery. Pharm Sci Techn Today. 1998 ; 1: 328-335
7. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2009 ; 62: 83-99
8. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev. 2002 ; 54: 37-51
9. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004 ; 58: 409-426
10. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials. 2000 ; 21: 2155-2161
11. Dai HJ, Chen Q, Qin HL, Guan Y, Shen DY, Hua YQ, et al. A temperature-responsive copolymer hydrogel in controlled drug delivery. Macromolecules. 2006 ; 39: 6584-6589
12. Ho EA, Vassileva V, Allen C, Piquette-Miller M. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. J Control Release. 2005 ; 104: 181-191
13. Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliv Rev. 2002 ; 54: 53-77
14. Lee KY, Ha WS, Park WH. Blood compatibility and biodegradability of partially n-acylated chitosan derivatives. Biomaterials. 1995 ; 16: 1211-1216
15. Wu J, Wei W, Wang LY, Su ZG, Ma GH. A thermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system. Biomaterials. 2007 ; 28: 2220-2232
16. Berger J, Reist M, Mayer JM, Felt O, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm. 2004 ; 57: 35-52
17. Wu J, Su ZG, Ma GH. A thermo- and ph-sensitive hydrogel composed of quaternized chitosan/glycerophosphate. Int J Pharm. 2006 ; 315: 1-11
18. Cho J, Heuzey MC, Begin A, Carreau PJ. Physical gelation of chitosan in the presence of β-glycerophosphate: the effect of temperature. Biomacromolecules. 2005 ; 6: 3267-3275
19. Crompton KE, Goud JD, Bellamkond RV, Gengenbach TR, Finkelstein DI, Forsythe JS. Polylysine-functionalised thermoresponsive chitosan hydrogel for neural tissue engineering. Biomaterials. 2007 ; 28: 441-449
20. Hoemann CD, Chenite A, Sun J, Hurtig M, Serreqi A, Buschmann MD. Cytocompatible gel formation of chitosan-glycerol phosphate solutions supplemented with hydroxyl ethyl cellulose is due to the presence of glyoxal. J Biomed Mater Res A. 2007 ; 56: 521-529
21. Ruel-Gariepy E, Chenite A, Chaput C, Guirguis S, Leroux JC. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs. Int J Pharm. 2000 ; 203: 89-98
22. Jeong B, Bae YH, Kim SW. Thermoreversible gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions. Macromolecules. 1999 ; 32: 7064-7069
23. Lederer CM, Harold RE. Drop size of commercial glaucoma medications. Am J Ophthal. 1986 ; 101: 691-694
24. Desai SD, Blanchard J. In vitro evaluation of pluronic f127-based controlled-release ocular delivery systems for pilocarpine. J Pharm Sci. 1998 ; 87: 226-230
25. Schoenwald RD, Huang HS. Corneal penetration behavior of beta-blocking-agents.1. Physicochemical factors. J Pharm Sci. 1983 ; 72: 1266-1272
26. Draize JH, Woodard G, Calvery HO. methods for the study of irritation and toxicity of substances. J Pharmacol Exp Ther. 1944 ; 82: 377-390
27. Edsman K, Carlfors J, Harju K. Rheological evaluation and ocular contact time of some carbomer gels for ophthalmic use. Int J Pharm. 1996 ; 137: 233-241
28. Calonge MC, Pastor JC, Herreras JM, Gonzalez JL. Pharmacologic modulation of vascular permeability in ocular allergy in the rat. Invest Ophthalmol Vis Sci. 1990 ; 31: 176-180
29. Schoch C. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and acular immediate hypersensitivity in the albino rat. Ocul Immunol Inflamm. 2005 ; 13: 39-44
30. Harada M, Takeuchi M, Fukao T, Katagiri K. Simple method for quantitative extraction of dye extravasated into skin. J Pharm Pharmacol. 1971 ; 23: 218-219
31. Qi HY, Chen WW, Huang CY, Li L, Chen CM, Li WM, et al. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm. 2007 ; 337: 178-187
32. Chenite A, Buschmann M, Wang D, Chaput C, Kandani N. Rheological characterization of thermogelling chitosan/glycerol-phosphate solutions. Carbohydr Polym. 2001 ; 46: 39-47
33. Hirano S, Yamaguchi R, Fukui N, Iwata M. A Chitosan oxalate gel: its conversion to an N-acetylchitosan gel via a chitosan gel. Carbohydr Res. 1990 ; 201: 145-149
34. Draget KI, Varum KM, Moen E, Gynnild H, Smidsrod O. Chitosan cross-linked with Mo(VI) polyoxyanions: a new gelling system. Biomaterials. 1992 ; 13: 635-638
35. Back JF, Oakenfull D, Smith MB. Increased thermal stability of proteins in the presence of sugars and polyols. Biochemistry. 1979 ; 8: 5191-5196
36. Ahmadi R, Bruijn JDD. Biocompatibility and gelation of chitosan-glycerol phosphate hydrogels. J Biomed Mater Res A. 2008 ; 86: 824-832
37. Cho J, Heuzey MC, Begin A, Carreau PJ. Chitosan and glycerophosphate concentration dependence of solution behaviour and gel point using small amplitude oscillatory rheometry. Food Hydrocolloid. 2006 ; 20: 936-945
38. Ganji F, Abdekhodaie M, Ramazani SAA. Gelation time and degradation rate of chitosan-based injectable hydrogel. J Sol-Gel Sci Technol. 2007 ; 42: 47-53
39. Zhou HY, Chen XG, Kong M, Liu CS, Cha DS, Kennedy JF. Effect of molecular weight and degree of chitosan deacetylation on the preparation and characteristics of chitosan thermosensitive hydrogel as a delivery system. Carbohydr Polym. 2008 ; 73: 265-273
40. Ta HT, Han H, Larson I, Dass CR, Dunstan DE. Chitosan-dibasic orthophosphate hydrogel: a potential drug delivery system. Int J Pharm. 2009 ; 371: 134-141
41. Benedetti MS, Plisnier M, Kaise J, Maier L, Baltes E, Arendt C, et al. Absorption, distribution, metabolism and excretion of 14C levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 2001 ; 57: 571-582
42. Tillement JP, Testa B, Bree F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003 ; 66: 1123-1126
43. Pagliara A, Testa B, Carrupt PA, Jolliet P, Morin C, Morin D, et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J Med Chem. 1998 ; 41: 853-863
44. Di CG, Burgalassi S, Zambito Y, Monti D, Chetoni P. Effects of different N-trimethyl chitosans on in vitro/in vivo ofloxacin transcorneal permeation. J Pharm Sci. 2004 ; 93: 2851-2862
45. Di CG, Zambito Y, Burgalassi S, Nardini I, Saettone MF. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm. 2005 ; 273: 37-44
46. Schipper NGM, Olsson S, Hoogstraate JA, deBoer AG, Vårum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res. 1997 ; 14: 923-929
47. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005 ; 102: 23-38
48. Abelson MB, Sloan JE, Mooshian M. Basis of ocular allergy and mechanisms for successful management. Ophthalmoic Practice. 1993 ; 11: 278-287
49. Jaanus SD, Hegeman SL, Swanson MW Clinical ocular pharmacology. Bartlett JD Jaanus SD, ed. Boston: Butterworth-Heinemann ; 1995: 337-353.
50. Walsh GM. A review of the role of levocetirizine as an effective therapy for allergic disease. Expert Opin Pharmacother. 2008 ; 9: 859-867
51. Minami K, Kamei C. A chronic model for evaluating the itching associated with allergic conjunctivitis in rats. Int Immunopharmacol. 2004 ; 4: 101-108
52. Bayer A, Uludag HA, Sobaci G, Mutlu FM. Comparison of antiallergic drugs in an experimental model of ocular anaphylaxis. Ophthalmologica. 2003 ; 217: 119-123
53. Calonge M, Siemasko KF, Stern ME. Animal models of ocular allergy and their clinical correlations. Curr Allergy Asthma Rep. 2003 ; 3: 345-351
54. Shoji J, Sakimoto T, Muromoto K, Inada N, Sawa M, Ra C. Comparison of topical dexamethasone and topical FK506 treatment for the experimental allergic conjunctivitis model in BALB/c mice. Jpn J Ophthalmol. 2005 ; 9: 205-210
55. Groneberg DA, Bielory L, Fischer A, Bonini S, Wahn U. Animal models of allergic and inflammatory conjunctivitis. Allergy. 2003 ; 58: 1101-1113
56. Khosravi E, Elena PP, Hariton C. Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs. Inflamm Res. 1995 ; 44: 47-54
57. Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, Rodriguez AE, Pastor S. Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. Exper Eye Res. 2008 ; 86: 791-797